


Amendments to the Claims:

Claims 1, 6-10, 12-30, 32-43, 48-52, 54-64, 69-73 and 75-91 are pending in this application. Claims 2-5, 11, 31, 44-47, 53, 65-68, 74, 92-101 were previously canceled in Applicants' amendment mailed July 11, 2003, without prejudice or disclaimer. Upon entry of the present amendment, claims 1, 30, 32, 43, 64 and 88 are amended and claims 90 and 91 are canceled. Claims 6-9, 12-13, 22, 42, 54-55, 69-72, 75-76 and 88 were previously presented. Claims 10, 14-21, 23-29, 33-41, 48-52, 56-63, 73, 77-87 and 89 are unchanged from the original. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound having the formula:



wherein

W is N;

X is CH;

Y is selected from the group consisting of O, S and N(R);

wherein R is selected from the group consisting of H, CN, NO₂, (C₁-C₁₀)alkyl, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)alkenyl and (C₂-C₁₀)alkynyl;

Z is selected from the group consisting of H, (C₁-C₁₀)alkyl, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl and NR²R³;

R¹, R² and R³ are independently selected from the group consisting of H, (C₁-C₁₀)alkyl, (C₃-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, (C₁-C₁₀)heteroalkyl, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl, aryl, aryl(C₁-

C₄)alkyl, aryl(C₁-C₄)heteroalkyl, heteroaryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)heteroalkyl and perfluoro(C₁-C₆)alkyl; and wherein when Z is NR²R³, R² and R³ can be combined to form a 5- to 7-membered heterocyclcyl ring;

R⁴ is selected from the group consisting of H, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₄-C₇)cycloalkyl-alkyl, (C₂-C₆)alkenyl and (C₂-C₆)alkynyl;

A is a substituted or unsubstituted 6-membered fused carbocyclic or heterocyclic aromatic ring system, wherein the heterocyclic aromatic ring system contains 1-2 N atoms; and

B is a substituted or unsubstituted five- or six-membered ring which is aromatic, containing at least one nitrogen atom, and from 0 to 3 additional heteroatoms, wherein the B ring substituents are selected from the group consisting of halogen, CF₃, CF₃O, (C₁-C₆)alkyl, perfluoro(C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)heteroalkyl, (C₁-C₆)alkoxy, (C₁-C₆)thioalkoxy, amino, (C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl, cyano, nitro, sulfonamido, (C₁-C₆)acyl, (C₁-C₆)acylamino, (C₁-C₆)alkoxycarbonyl, (C₁-C₆)alkoxycarbonyl(C₁-C₆)alkyl, carboxamido and (C₁-C₆)heteroalkoxy;

and pharmaceutically acceptable salts thereof.

2.-5. (Canceled)

6. (Previously Presented) A compound of claim 1, wherein Y is selected from the group consisting of O and S.

7. (Previously Presented) A compound of claim 1, wherein Y is O.


8. (Previously Presented) A compound of claim 1, wherein Y is S.

9. (Previously Presented) A compound of claim 1, wherein Z is NR²R³.

10. (Original) A compound of claim 6, wherein R⁴ is H.

11. (Canceled)


12. (Previously Presented) A compound of claim 1, wherein A is selected from the group consisting of:



wherein

R⁵, R⁶, R⁷ and R⁸ are independently selected from the group consisting of H, halogen, CF₃, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)heteroalkyl, (C₁-C₆)alkoxy, (C₁-C₆)thioalkoxy, amino, (C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl, (C₃-C₁₀)cycloheteroalkyl-alkyl, cyano, nitro, (C₁-C₆)acyl, (C₁-C₆)acylamino, (C₁-C₆)alkoxycarbonyl, (C₁-C₆)alkoxycarbonyl (C₁-C₆)alkyl, CONH₂, CO-NH-(C₁-C₆)alkyl, CO-N[(C₁-C₆)alkyl]₂, SO₂NH₂, SO₂NH-(C₁-C₆)alkyl, SO₂N-[(C₁-C₆)alkyl]₂ and (C₁-C₆)heteroalkoxy; or two adjacent R groups selected from R⁵, R⁶, R⁷ and R⁸, can be linked together to form a new 5- or 6-membered carbocyclic or heterocyclic ring.

13. (Previously Presented) A compound of claim 12, wherein Y is O or S; and A is selected from the group consisting of:



14. (Original) A compound of claim 1, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

15. (Original) A compound of claim 1, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.

16. (Original) A compound of claim 1, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

17. (Original) A compound of claim 1, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.


18. (Original) A compound of claim 13, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

19. (Original) A compound of claim 13, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.

20. (Original) A compound of claim 13, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

21. (Original) A compound of claim 13, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.

22. (Previously Presented) A compound of claim 1, wherein Y is O or S; Z is H, CH₃, NH₂ or NHCH₃; R¹ is H, (C₁-C₆)alkyl, (C₁-C₁₀)heteroalkyl, (C₄-C₁₀)cycloheteroalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl, aryl(C₁-C₄)alkyl, aryl(C₁-C₄)heteroalkyl, heteroaryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)heteroalkyl, or perfluoro(C₁-C₆)alkyl; R⁴ is H; A represents



wherein R⁶ and R⁷ are independently selected from the group consisting of H, halogen, CF₃, CF₃O, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₂-C₄)alkynyl, (C₁-C₄)heteroalkyl, (C₃-C₁₀)cycloheteroalkyl-alkyl and cyano; and B is a five-membered aromatic ring system containing at least one nitrogen atom.

23. (Original) A compound of claim 22, wherein Y is S.
24. (Original) A compound of claim 22, wherein Z is NR²R³.
25. (Original) A compound of claim 22, wherein Z is NH₂.
26. (Original) A compound of claim 22, wherein R¹ is (C₁-C₆)alkyl, (C₁-C₆)heteroalkyl or (C₃-C₁₀)cycloheteroalkyl-alkyl.
27. (Original) A compound of claim 22, wherein B is a five-membered aromatic ring system containing 1-2 nitrogen atoms and 0-1 sulfur atoms.
28. (Original) A compound of claim 27, wherein B is unsubstituted or substituted by (C₁-C₃)alkyl, CF₃, cyano, or halogen.
29. (Original) A compound of claim 22, wherein Z is NH₂; R⁶ is selected from the group consisting of H, halogen, CF₃, CF₃O, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₁-C₄)heteroalkyl, (C₃-C₁₀)cycloheteroalkyl-alkyl and cyano, wherein the alkyl, alkenyl and heteroalkyl groups optionally bear additional substituents selected from cyano, carboxamido, (C₁-C₃)alkylsulfonyl or (C₁-C₃)alkoxy; and R⁷ is selected from the group consisting of H, halogen, CF₃, CF₃O, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₂-C₄)alkynyl, (C₁-C₄)heteroalkyl and cyano.


30. (Currently Amended) A compound of claim 29, wherein R^6 is selected from the group consisting of $CH_2(CH_2)[[m]]_nCN$, $CH_2(CH_2)_nSO_2CH_3$ and $CH_2(CH_2)_nOCH_3$, wherein the subscript n is an integer from 0 to 2.

31. (Canceled)

32. (Currently Amended) A compound of claim 29, wherein R^7 is selected from the group consisting of H, halogen, CF_3 and $(C_1-C_4)alkyl$.

33. (Original) A compound of claim 29, wherein R^7 is methyl.

34. (Original) A compound of claim 1, having the formula:



wherein Y is O, S or N-CN; W' is $N(CH_3)$, $N(CF_3)$, $N(CH_2CH_3)$, O or S; the subscripts n and n' are independently integers from 0 to 3; R^7 is H, halogen, CF_3 , CF_3O , $(C_1-C_4)alkyl$, $(C_2-C_4)alkenyl$, $(C_2-C_4)alkynyl$, $(C_1-C_4)heteroalkyl$ or cyano; R^9 is CN, $CONH_2$, $CO-NH-(C_1-C_6)alkyl$, $CO-N[(C_1-C_6)alkyl]_2$, $CO-NH-(C_1-C_6)heteroalkyl$, $CO-N[(C_1-C_6)heteroalkyl]_2$, $S(O)_{n''}-(C_1-C_6)alkyl$, $S(O)_{n''}-(C_1-C_6)heteroalkyl$, heteroaryl, $(C_1-C_6)alkoxy$ or $(C_3-C_6)cycloheteroalkyl$, wherein each n'' is independently an integer of 0 to 2; R^{10} is NH_2 , $NH-(C_1-C_6)alkyl$, $N[(C_1-C_6)alkyl]_2$, $NH-(C_1-C_6)heteroalkyl$, $N[(C_1-C_6)heteroalkyl]_2$, $(C_1-C_6)heteroalkyl$, $S(O)_{n''}-(C_1-C_6)alkyl$, $S(O)_{n''}-(C_1-C_6)heteroalkyl$, aryl, heteroaryl, $O-(C_1-C_6)alkyl$, $O-(C_1-C_6)heteroalkyl$ or $(C_3-C_8)cycloheteroalkyl$; and R^{11} is H, CF_3 , NH_2 , $NH-(C_1-C_6)alkyl$, $N[(C_1-C_6)alkyl]_2$, halogen or $(C_1-C_3)alkyl$.

35. (Original) A compound of claim **34**, wherein Y is O or S; W' is N-CH₃; n is 2; n' is 1-3; R⁹ is cyano, CONH₂, SO₂-(C₁-C₆)alkyl, (C₁-C₆)alkoxy or (C₃-C₆)cycloheteroalkyl; R¹⁰ is NH-(C₁-C₆)alkyl, N[(C₁-C₆)alkyl]₂, NH-(C₁-C₆)heteroalkyl, N[(C₁-C₆)heteroalkyl]₂, O-(C₁-C₆)alkyl, O-(C₁-C₆)heteroalkyl, (C₁-C₆)alkoxy or (C₃-C₈)cycloheteroalkyl; and R¹¹ is H.

36. (Original) A compound of claim **22**, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

37. (Original) A compound of claim **22**, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.







38. (Original) A compound of claim **22**, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.













39. (Original) A compound of claim **22**, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

40. (Original) A compound of claim **1**, wherein Y is S; Z is NH₂ and R¹ is (C₁-C₆)alkyl.


41. (Original) A compound of claim **40**, wherein R¹ is methyl.

42. (Previously Presented) A compound of claim 1, wherein said compound is selected from the group consisting of:





43. (Currently Amended) A composition comprising a pharmaceutically acceptable excipient and a compound having the formula:



wherein

W is N;

X is CH;

Y is selected from the group consisting of O, S and N(R);

wherein R is selected from the group consisting of H, CN, NO₂, (C₁-C₁₀)alkyl, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)alkenyl and (C₂-C₁₀)alkynyl;

Z is selected from the group consisting of H, (C₁-C₁₀)alkyl, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl and NR²R³;

R¹, R² and R³ are independently selected from the group consisting of H, (C₁-C₁₀)alkyl, (C₃-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, (C₂-C₁₀)heteroalkyl, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl, aryl, aryl(C₁-C₄)alkyl, aryl(C₂-C₄)heteroalkyl, heteroaryl(C₂-C₄)alkyl, heteroaryl(C₂-C₄)heteroalkyl and perfluoro(C₁-C₆)alkyl; and wherein when Z is NR²R³, R² and R³ can be combined to form a 5- to 7-membered ring; and wherein when Y is N(R), R and R¹ are optionally combined to form a 5- to 7-membered ring;

R⁴ is selected from the group consisting of H, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₄-C₇)cycloalkyl-alkyl, (C₂-C₆)alkenyl and (C₂-C₆)alkynyl;

A is a substituted or unsubstituted 6-membered fused carbocyclic or heterocyclic aromatic ring system, wherein the heterocyclic aromatic ring system contains 1-2 N atoms; and

B is a substituted or unsubstituted five- or six-membered ring which is aromatic, containing at least one nitrogen atom, and from 0 to 3 additional heteroatoms, wherein the B ring substituents are selected from the group consisting of halogen, CF₃, CF₃O, (C₁-C₆)alkyl, perfluoro(C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)heteroalkyl, (C₁-C₆)alkoxy, (C₁-C₆)thioalkoxy, amino, (C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl, cyano, nitro, sulfonamido, (C₁-C₆)acyl, (C₁-C₆)acylamino, (C₂-C₆)alkoxycarbonyl, (C₂-C₆)alkoxycarbonyl(C₁-C₆)alkyl, carboxamido and (C₁-C₆)heteroalkoxy;

and pharmaceutically acceptable salts thereof.

44.-47. (Canceled)

48. (Original) A composition in accordance with claim 43, wherein Y is selected from the group consisting of O and S.

49. (Original) A composition in accordance claim 43, wherein Y is O.


50. (Original) A composition in accordance claim 43, wherein Y is S.

51. (Original) A composition in accordance claim 43, wherein Z is NR²R³.

52. (Original) A composition in accordance with claim 48, wherein R⁴ is H.

53. (Canceled)


54. (Previously Presented) A composition in accordance with claim 43, wherein A is selected from the group consisting of:



wherein

R^5 , R^6 , R^7 and R^8 are independently selected from the group consisting of H, halogen, CF_3 , (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) heteroalkyl, (C_1-C_6) alkoxy, (C_1-C_6) thioalkoxy, amino, (C_1-C_6) alkylamino, di (C_1-C_6) alkylamino, (C_3-C_{10}) cycloalkyl, (C_4-C_{10}) cycloalkyl-alkyl, (C_3-C_{10}) cycloheteroalkyl, (C_3-C_{10}) cycloheteroalkyl-alkyl, cyano, nitro, (C_1-C_6) acyl, (C_1-C_6) acylamino, (C_2-C_6) alkoxycarbonyl, (C_3-C_6) alkoxycarbonylalkyl, $CONH_2$, $CO-NH-(C_1-C_6)$ alkyl, $CO-N[(C_1-C_6)alkyl]_2$, SO_2NH_2 , $SO_2NH-(C_1-C_6)alkyl$, $SO_2N-[(C_1-C_6)alkyl]_2$ and (C_1-C_6) heteroalkoxy; or two adjacent R groups can be linked together to form a new 5- or 6-membered carbocyclic or heterocyclic ring.

55. (Previously Presented) A composition in accordance with claim 43, wherein Y is O or S; and A is selected from the group consisting of:



56. (Original) A composition in accordance with claim 43, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

57. (Original) A composition in accordance with claim 43, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.

58. (Original) A composition in accordance with claim 43, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

59. (Original) A composition in accordance with claim 43, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.


60. (Original) A composition in accordance with claim 55, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

61. (Original) A composition in accordance with claim 55, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.

62. (Original) A composition in accordance with claim 55, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

63. (Original) A composition in accordance with claim 55, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.

64. (Currently Amended) A method for treating rheumatoid arthritis ~~an inflammatory condition or cancer~~, said method comprising administering to a subject in need of such treatment, an effective amount of a compound having the formula:



wherein

W is N;

X is CH;

Y is selected from the group consisting of O, S and N(R);

wherein R is selected from the group consisting of H, CN, NO₂, (C₁-C₁₀)alkyl, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)alkenyl and (C₂-C₁₀)alkynyl;

Z is selected from the group consisting of H, (C₁-C₁₀)alkyl, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₂-C₁₀)alkenyl, (C₂-C₁₀)alkynyl and NR²R³;

R¹, R² and R³ are independently selected from the group consisting of H, (C₁-C₁₀)alkyl, (C₃-C₁₀)alkenyl, (C₂-C₁₀)alkynyl, (C₂-C₁₀)heteroalkyl, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl, aryl, aryl(C₁-C₄)alkyl, aryl(C₂-C₄)heteroalkyl, heteroaryl(C₂-C₄)alkyl, heteroaryl(C₂-C₄)heteroalkyl and perfluoro(C₁-C₆)alkyl; and wherein when Z is NR²R³, R² and R³ can be combined to form a 5- to 7-membered ring; and wherein when Y is N(R), R and R¹ are optionally combined to form a 5- to 7-membered ring;

R⁴ is selected from the group consisting of H, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₄-C₇)cycloalkyl-alkyl, (C₂-C₆)alkenyl and (C₂-C₆)alkynyl;

A is a substituted or unsubstituted 6-membered fused carbocyclic or heterocyclic aromatic ring system, wherein the heterocyclic aromatic ring system contains 1-2 N atoms; and

B is a substituted or unsubstituted five- or six-membered ring which is aromatic, containing at least one nitrogen atom, and from 0 to 3 additional heteroatoms; wherein the B ring substituents are selected from the group consisting of halogen, CF₃, CF₃O, (C₁-C₆)alkyl, perfluoro(C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)heteroalkyl, (C₁-C₆)alkoxy, (C₁-C₆)thioalkoxy, amino, (C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, (C₃-C₁₀)cycloalkyl, (C₄-C₁₀)cycloalkyl-alkyl, (C₃-C₁₀)cycloheteroalkyl, cyano, nitro, sulfonamido, (C₁-C₆)acyl, (C₁-C₆)acylamino, (C₂-C₆)alkoxycarbonyl, (C₂-C₆)alkoxycarbonyl(C₁-C₆)alkyl, carboxamido and (C₁-C₆)heteroalkoxy;

and pharmaceutically acceptable salts thereof.

65.-68. (Canceled)

69. (Previously Presented) A method in accordance with claim 64, wherein Y is selected from the group consisting of O and S.

70. (Previously Presented) A method in accordance with claim 64, wherein Y is O.


71. (Previously Presented) A method in accordance with claim 64, wherein Y is S.

72. (Previously Presented) A method in accordance with claim 64, wherein Z is NR^2R^3 .

73. (Original) A method in accordance with claim 69, wherein R^4 is H.

74. (Canceled)

75. (Previously Presented) A method in accordance with claim 64, wherein A is selected from the group consisting of:




wherein

R^5 , R^6 , R^7 and R^8 are independently selected from the group consisting of H, halogen, CF_3 , $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_2\text{-C}_6)\text{alkenyl}$, $(\text{C}_2\text{-C}_6)\text{alkynyl}$, $(\text{C}_1\text{-C}_6)\text{heteroalkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, $(\text{C}_1\text{-C}_6)\text{thioalkoxy}$, amino, $(\text{C}_1\text{-C}_6)\text{alkylamino}$, $\text{di}(\text{C}_1\text{-C}_6)\text{alkylamino}$, $(\text{C}_3\text{-C}_{10})\text{cycloalkyl}$, $(\text{C}_4\text{-C}_{10})\text{cycloalkyl-alkyl}$, $(\text{C}_3\text{-C}_{10})\text{cycloheteroalkyl}$, $(\text{C}_3\text{-C}_{10})\text{cycloheteroalkyl-alkyl}$, cyano, nitro, $(\text{C}_1\text{-C}_6)\text{acyl}$, $(\text{C}_1\text{-C}_6)\text{acylamino}$, $(\text{C}_2\text{-C}_6)\text{alkoxycarbonyl}$, $(\text{C}_3\text{-C}_6)\text{alkoxycarbonylalkyl}$, CONH_2 , $\text{CO-NH}(\text{C}_1\text{-C}_6)\text{alkyl}$, $\text{CO-N}[(\text{C}_1\text{-C}_6)\text{alkyl}]_2$, SO_2NH_2 , $\text{SO}_2\text{NH}(\text{C}_1\text{-C}_6)\text{alkyl}$, $\text{SO}_2\text{N}[(\text{C}_1\text{-C}_6)\text{alkyl}]_2$

and (C₁-C₆)heteroalkoxy; or two adjacent R groups can be linked together to form a new 5- or 6-membered carbocyclic or heterocyclic ring.

76. (Previously Presented) A method in accordance with claim 64, wherein Y is O or S; and A is selected from the group consisting of:



77. (Original) A method in accordance with claim 64, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

78. (Original) A method in accordance with claim 64, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.

79. (Original) A method in accordance with claim 64, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

80. (Original) A method in accordance with claim 64, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.

81. (Original) A method in accordance with claim 76, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

82. (Original) A method in accordance with claim 76, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.

83. (Original) A method in accordance with claim 76, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

84. (Original) A method in accordance with claim 76, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.

85. (Original) A method in accordance with claim 64, wherein said compound is administered orally.

86. (Original) A method in accordance with claim 64, wherein said compound is administered topically.

87. (Original) A method in accordance with claim 64, wherein said compound is administered intravenously or intramuscularly.

88. (Currently Amended) A method in accordance with claim 64, wherein said compound is administered in combination with a second therapeutic agent, said second therapeutic agent being a member selected from the group consisting of prednisone, dexamethasone, beclomethasone, methylprednisone, betamethasone, hydrocortisone, methotrexate, cyclosporin, rapamycin, tacrolimus, antihistamine drugs, TNF antibodies, IL-1 antibodies, soluble TNF receptors, soluble IL-1 receptors, TNF or IL-1 receptor antagonists, non-steroidal antiinflammatory agents, COX-2 inhibitors, ~~antidiabetic agents, and anticancer agents.~~

Appl. No. 10/004,287
Amdt. dated February 27, 2004
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group

PATENT

89. (Original) A method in accordance with claim **88**, wherein said administering is sequential.

90. - 101. (Canceled)